ABOUT NORTHX BIOLOGICS

We are a Swedish CDMO with more than thirty years of GMP biologics experience. In 2021, the Swedish Government designated us as a national competence centre for advanced biologics and gene therapies — a recognition that reflects what we had already been doing for years: integrating with client teams from the earliest stages of development, not arriving at the point of manufacturing handover.

We work across any product expressed from a microbial or mammalian system, and what distinguishes us is not the breadth of that list but the depth behind it. We have navigated the regulatory, technical and operational challenges of biologics manufacturing across modalities and across decades. When a biotech company brings us their science, we treat it as our own. And we stay involved until it reaches patients. We go always BEYOND the expected.

Who are we?

Why are we getting involved as a sponsor?

We exists at the intersection of science and manufacturing, and the Swedish biotech community is where many of the programmes we work on begin. Supporting BiotechBuilders is a natural extension of how we already work: openly, collaboratively, and with a genuine interest in the health of the ecosystem around us. We benefit from the connections and the conversations. And if one of those conversations helps an early-stage company ask the right manufacturing questions earlier, that matters to us in a very direct way.

What challenges and opportunities do we currently see in the industry?

The science has never been more promising: advances in cell and gene therapy, biologics and precision medicine are creating genuine new options for patients who previously had none. The challenge is translating that science into reliable, scalable manufacturing, which remains complex and takes years to build.

For the Nordic region, the scientific foundation is strong. What the sector needs now is policy and funding continuity to match it, including support during the periods between programmes. Manufacturing capacity and expertise cannot be switched on and off. When funding gaps force organisations to scale down, capability that took years to build can disappear quickly. Preparedness depends on keeping that infrastructure and those teams intact.

Closer collaboration between academia, industry, CDMOs and policymakers is the other piece. The Nordic region has all the ingredients. Connecting them more deliberately is what turns scientific promise into patient access.

What is currently at the top of our company’s agenda?

Right now, we are focused on expanding our capabilities across a broader range of biologics modalities and development stages: investing in facilities, deepening our scientific and operational expertise, and extending our reach to clients in new markets.

But underpinning all of it is something less visible and equally important, making sure that as we grow, the way we work does not change. The reason clients choose us goes beyond capacity. It is the quality of the team they get access to, the depth of process knowledge that team carries, and the fact that we treat their programme as our responsibility rather than our contract. Scaling that model without diluting it is the real agenda.